DEAR EDITOR, Exacerbation/reactivation of chronic hepatitis B virus (HBV) and hepatitis C
virus (HCV) in people with psoriasis during treatment with biologics is a concern with the use …

MADAM, The reactivation of the hepatitis B virus (HBV) during immunosuppressive therapy
has already been reported, even in hepatitis B surface antigen (HBsAg)-negative patients …

Hepatitis B virus reactivation after ustekinumab treatment: reply from authors Page 1 while
HbsAg is negative in the serum. Occult HBV infection is classified into two groups based on HBV …

DEAR EDITOR, Ustekinumab is a human monoclonal antibody directed against the p40
subunit of both interleukin (IL)-12 and IL-23. 1 It has been shown to be very effective in …

Dear Editor: Psoriasis is a chronic, inflammatory, and immune-mediated disease with a high
morbidity rate in affected patients. The advent of biologics that target specific molecules in …

DEAR EDITOR, Psoriasis is an inflammatory skin disease that affects approximately 2–3% of
the population. 1 Patients with psoriasis are at risk of developing psoriatic arthritis (PsA), an …

DEAR EDITOR, Despite the availability of highly efficacious biologics, psoriasis still remains
an area of medical need. 1, 2 In particular, manifestations of the disease in different organs …

DEAR EDITOR, Several therapeutic antibodies are available for the treatment of chronic
plaque-type psoriasis. Ustekinumab (a monoclonal interleukin-12/23 antagonist) is one of …

DEAR EDITOR, Ustekinumab is a fully human monoclonal antibody that targets the common
p40 subunit shared by interleukins (IL)-12 and IL-23, approved in the USA and Europe in …

DEAR EDITOR, Currently available biologics for psoriasis target the function of tumour
necrosis factor (TNF)-a, interleukin (IL)-17A or IL-12/23, and include etanercept (anti-TNF …